ITM

ITM, founded in 2004, is a prominent radiopharmaceutical biotechnology company specializing in the development and production of targeted therapeutics and diagnostics for oncology. The firm focuses on addressing the needs of cancer patients and clinicians by leveraging high-quality medical radioisotopes. By integrating these isotopes with advanced targeting molecules, ITM maintains a robust precision oncology pipeline that includes multiple Phase 3 clinical trials. The company’s commitment to improving patient outcomes is supported by two decades of pioneering expertise in radiopharma, positioning it as a central player in the global healthcare sector.

Operating with a workforce of 500-1,000 employees, ITM maintains a sophisticated organizational structure designed to support complex biotech research and global supply chain operations. The company’s internal expertise spans engineering, medical research, and clinical development, ensuring high standards in GMP-compliant laboratory environments. Meet ITM's team to learn more about the leadership and specialized professionals driving these innovations. This multidisciplinary approach allows the firm to effectively manage its broad pipeline and maintain its competitive edge in the rapidly evolving field of targeted cancer treatment.

ITM has demonstrated significant financial growth, reporting annual revenue of $230.6M. The company’s strategic funding history includes substantial private equity and debt financing from major global investors, which supports its ongoing research and development initiatives. Explore financial highlights to review the company's fiscal performance and capital structure. With a strong focus on precision medicine and an established global network, ITM continues to advance its mission of providing effective, targeted therapies to improve the quality of life for patients worldwide.